Clinicopathological profile of lung cancer at a tertiary care center

BACKGROUND: Lung cancer is one of the most common malignancies with high morbidity and mortality. Nonsmall cell lung cancer (NSCLC) accounts for majority of cases. AIMS: This study aims to study the clinical and pathological features of lung cancer patients treated at our institute between January 2...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of cancer 2018-07, Vol.55 (3), p.273-275
Main Authors: Dattatreya, Satya, Bansal, Rekha, Vamsy, Mohana, Vaniawala, Salil, Nirni, S, Dayal, Monal, Sharma, Rakesh
Format: Article
Language:English
Subjects:
Age groups
Analysis
Cancer patients
Cancer research
Cancer therapies
Care and treatment
Epidermal growth factors
Females
Histology
India
Kinases
Lung cancer
Medical research
Metastasis
Morbidity
Mortality
Mutation
Non-Hodgkin's lymphomas
Non-small cell lung cancer
Smoking
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Lung cancer is one of the most common malignancies with high morbidity and mortality. Nonsmall cell lung cancer (NSCLC) accounts for majority of cases. AIMS: This study aims to study the clinical and pathological features of lung cancer patients treated at our institute between January 2011 and December 2016. SUBJECTS AND METHODS: It is a retrospective study. 446 patients of lung cancer were retrospectively analyzed for demographic data, history of smoking, histological type, and presence of epidermal growth factor receptor (EGFR) mutation/anaplastic lymphoma kinase (ALK) mutations. RESULTS: Of the 446 patients analyzed, 304 (68%) were males and 142 (32%) were females, with the ratio being 2:1. Most of our patients had a lesion localizing to the right side (45.7%) than left (37.8%). NSCLC was reported in 81.1% of our patients. EGFR mutation was found in 60 (24%) patients, the most common mutation being the deletion of exon 19 (73%) followed by L858R mutation (21.6%). CONCLUSIONS: EGFR and ALK mutation testing of all the lung cancer patients is to be encouraged as these mutations form druggable targets.
ISSN:0019-509X
1998-4774
DOI:10.4103/ijc.IJC_455_17